Cargando…

Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)

The aim of this study was to evaluate the usefulness of EGFR mutation status in serum DNA as a means of predicting a benefit from gefitinib (IRESSA) therapy in Japanese patients with non-small cell lung cancer (NSCLC). We obtained pairs of tumour and serum samples from 42 patients treated with gefit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kimura, H, Suminoe, M, Kasahara, K, Sone, T, Araya, T, Tamori, S, Koizumi, F, Nishio, K, Miyamoto, K, Fujimura, M, Nakao, S
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360394/ https://www.ncbi.nlm.nih.gov/pubmed/17848912 http://dx.doi.org/10.1038/sj.bjc.6603949

Ejemplares similares

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
por: Kokubo, Y, et al.
Publicado: (2005)

EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib
por: Kimura, H, et al.
Publicado: (2006)

Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines
por: Maddineni, S B, et al.
Publicado: (2005)

Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
por: Blackledge, G, et al.
Publicado: (2004)

Additive interaction of gefitinib (‘Iressa’, ZD1839) and ionising radiation in human tumour cells in vitro
por: Giocanti, N, et al.
Publicado: (2004)

Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib
por: Lemos, C, et al.
Publicado: (2009)

Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer
por: Kirby, A M, et al.
Publicado: (2006)

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005)

Laminin-5 offsets the efficacy of gefitinib (‘Iressa’) in hepatocellular carcinoma cells
por: Giannelli, G, et al.
Publicado: (2004)

Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2
por: Nutt, J E, et al.
Publicado: (2004)

Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer
por: Yagi, H, et al.
Publicado: (2005)

Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway
por: Maseki, S, et al.
Publicado: (2012)

FGFR2 gene amplification and clinicopathological features in gastric cancer
por: Matsumoto, K, et al.
Publicado: (2012)

Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines
por: Nobuhara, Y, et al.
Publicado: (2005)

‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
por: Pallis, A G, et al.
Publicado: (2007)

Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer
por: Oshita, F, et al.
Publicado: (2006)

The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours
por: Knight, Louise A, et al.
Publicado: (2004)

Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma
por: Lemos-González, Y, et al.
Publicado: (2007)

Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity
por: Gooden, M J M, et al.
Publicado: (2014)

The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas
por: Shoji, K, et al.
Publicado: (2009)

Role of multifunctional transcription factor TFII-I and putative tumour suppressor DBC1 in cell cycle and DNA double strand damage repair
por: Tanikawa, M, et al.
Publicado: (2013)

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
por: Parra, H S, et al.
Publicado: (2004)

Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells
por: Okamoto, W, et al.
Publicado: (2011)

Tetraspanins CD9 and CD151, epidermal growth factor receptor and cyclooxygenase-2 expression predict malignant progression in oral epithelial dysplasia
por: Nankivell, P, et al.
Publicado: (2013)

Molecular determination of epidermal growth factor receptor in normal and neoplastic colorectal mucosa
por: Piazzi, G, et al.
Publicado: (2006)

Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status
por: Hofman, P, et al.
Publicado: (2008)

Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer
por: Sakakibara, T, et al.
Publicado: (2005)

Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma
por: Sonobe, M, et al.
Publicado: (2005)

Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis
por: Cho, W C S, et al.
Publicado: (2010)

Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer
por: Ishizuka, M, et al.
Publicado: (2013)

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer
por: Matsubara, J, et al.
Publicado: (2008)

miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer
por: Chiyomaru, T, et al.
Publicado: (2010)

Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer
por: Leung, W K, et al.
Publicado: (2005)

Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation
por: Noro, Rintaro, et al.
Publicado: (2006)

Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma
por: Kantola, T, et al.
Publicado: (2012)

Serum biomarker panels for the diagnosis of gastric adenocarcinoma
por: Ahn, H S, et al.
Publicado: (2012)

Regulation of anoikis resistance by NADPH oxidase 4 and epidermal growth factor receptor
por: Kim, Hyeryeong, et al.
Publicado: (2017)

Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer
por: Anderson, K S, et al.
Publicado: (2011)

Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma
por: Takemoto, S, et al.
Publicado: (2009)

Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer
por: Zeestraten, E C M, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_qglrifdr36corfue9ijvg9ngkj